Semprus BioSciences is a venture-backed biotechnology company developing functional surfaces to prevent medical device complications. Our initial product development efforts are focused on the first implantable and permanently antimicrobial surface technology. The intellectual property comes from the MIT labs of Prof. Robert Langer and Prof. Greg Stephanopoulos, and part of this scientific research was featured in Nature.  

The company targets both purchasers and the medical user:

• Our value proposition to purchasers is to reduce the likelihood of medical device complications, the costs of which usually comes out of a hospital's bottom line. 
• Our value proposition to medical users is to improve patient health and reduce liability without requiring a change in practices. 

The company's Chairman is Scott Rocklage, PhD, who is a partner at 5AM Ventures. Dr. Rocklage was the co-founder and CEO of Cubist Pharmaceuticals (NASDAQ: CBST).  This Cambridge, MA firm is headquartered in Kendall Square and has twelve full-time employees.